Allcyte GmbH of Austria has raised $6 million in seed financing to advance its artificial intelligence (AI) platform selecting treatments for late-stage blood cancers. The financing round was led by 42cap, Air Street capital, PUSH Ventures, Amino Collective and VP venture Partners. It follows results from a clinical trial which showed that the company’s real-time analysis of live tissue from cancer patients identified treatments for these patients that proved to be effective in 55% of cases.
